New drug combo could improve treatment for Hard-to-Treat colorectal cancer
NCT ID NCT07362836
First seen Feb 01, 2026 · Last updated May 15, 2026 · Updated 12 times
Summary
This phase 3 trial tests whether a new drug, fruquintinib, combined with chemotherapy works better than the standard treatment (bevacizumab plus chemo) for people with a specific type of advanced colorectal cancer (RAS-mutant). About 224 adults aged 18-75 with metastatic disease that has worsened after first-line therapy will be randomly assigned to one of the two treatments. The main goal is to see how long patients live without their cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.